ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review.Alzheimer's research & therapy · 2024Pooled it
- The Amyloid-β Pathway in Alzheimer's Disease.Molecular psychiatry · 2021Pooled it
- Effects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2024Trial
- Human tau pathology is associated with lonely, nontraveling slow waves linked to memory impairment.Nature neuroscience · 2026Article
- Regional Cerebrospinal Fluid Motility as a Key Determinant of Soluble Amyloid-β Levels and Kinetics.Research square · 2026Article
- Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer's disease.Communications medicine · 2026Article
- Associations of circulating resistin with Alzheimer's disease biomarkers and cognitive function in the preclinical stage of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2026Article
- Current Methods in Clinical Alzheimer's Disease Research and Diagnosis.Molecular diagnosis & therapy · 2025Review
- Navigating the blurred boundary: Neuropathologic changes versus clinical symptoms in Alzheimer's disease, and its consequences for research in genetics.Journal of Alzheimer's disease : JAD · 2025Review
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.European archives of psychiatry and clinical neuroscience · 2025Article
- Plasma phospho-tau217 as a predictive biomarker for Alzheimer's disease in a large south American cohort.Alzheimer's research & therapy · 2025Article
- Advances in blood biomarkers for Alzheimer disease (AD): A review.The Kaohsiung journal of medical sciences · 2024Review
- The Association Between Postural Sway and Preclinical Alzheimer Disease Among Community-Dwelling Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Is blood pTau a reliable indicator of the CSF status? A narrative review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.Nature medicine · 2024Article
- Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status.Alzheimer's research & therapy · 2024Article
- Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease.Molecular neurodegeneration · 2024Article
- The MINT Sprint 2.0: A picture naming test for detection of naming impairments in Alzheimer's disease and in preclinical AD.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Using cerebrospinal fluid biomarkers to diagnose Alzheimer's disease: an Australian perspective.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionCerebrospinal fluid (CSF) biomarkers can identify individuals with Alzheimer's disease (AD) pathology (eg, amyloid plaques, neurofibrillary tangles), but defined analyte cut-points using high-throughput automated assays are necessary for general clinical use.
methodsCSF amyloid β42 peptide (Aβ42), t-tau, and t-tau/Aβ42 were quantified by the Lumipulse platform in two test cohorts (A/B: Eisai BAN2401-201/MISSION AD E2609-301/302, n = 138; C: Knight Alzheimer's Disease Research Center (ADRC), n = 198), and receiver operating characteristic (ROC) curve analyses defined cut-points corresponding best to amyloid determinations using positron emission tomography (PET) imaging. The best-performing cut-point was then validated as a predictor of amyloid status in an independent cohort (D: MISSION AD E2609-301/302, n = 240).
resultsVirtually identical t-tau/Aβ42 cut-points (∼0.54) performed best in both test cohorts and with similar accuracy (areas under ROC curve [AUCs] [A/B: 0.95; C: 0.94]). The cut-point yielded an overall percent agreement with amyloid PET of 85.0% in validation cohort D. DISCUSSION: Lumipulse CSF biomarker measures with validated cut-points have clinical utility in identifying AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.